320 related articles for article (PubMed ID: 30587614)
1. Chitinase-3-like Protein 1 (YKL-40) Is Expressed in Lesional Skin in Hidradenitis Suppurativa.
Salomon J; Piotrowska A; Matusiak Ł; Dzięgiel P; Szepietowski JC
In Vivo; 2019; 33(1):141-143. PubMed ID: 30587614
[TBL] [Abstract][Full Text] [Related]
2. Inflammation induced changes in the expression levels of components of the microRNA maturation machinery Drosha, Dicer, Drosha co-factor DGRC8 and Exportin-5 in inflammatory lesions of hidradenitis suppurativa patients.
Hessam S; Sand M; Skrygan M; Gambichler T; Bechara FG
J Dermatol Sci; 2016 Jun; 82(3):166-74. PubMed ID: 26917346
[TBL] [Abstract][Full Text] [Related]
3. Chitinase-3-like Protein 1 (YKL-40): Novel Biomarker of Hidradenitis Suppurativa Disease Activity?
Matusiak Ł; Salomon J; Nowicka-Suszko D; Bieniek A; Szepietowski JC
Acta Derm Venereol; 2015 Jul; 95(6):736-7. PubMed ID: 25655759
[No Abstract] [Full Text] [Related]
4. MCPIP1/Regnase-1 Expression in Keratinocytes of Patients with Hidradenitis Suppurativa: Preliminary Results.
Krajewski PK; Szukała W; Lichawska-Cieślar A; Matusiak Ł; Jura J; Szepietowski JC
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298861
[TBL] [Abstract][Full Text] [Related]
5. Expression of miRNA-155, miRNA-223, miRNA-31, miRNA-21, miRNA-125b, and miRNA-146a in the Inflammatory Pathway of Hidradenitis Suppurativa.
Hessam S; Sand M; Skrygan M; Gambichler T; Bechara FG
Inflammation; 2017 Apr; 40(2):464-472. PubMed ID: 28028756
[TBL] [Abstract][Full Text] [Related]
6. Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers.
Vossen ARJV; van der Zee HH; Davelaar N; Mus AMC; van Doorn MBA; Prens EP
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):761-765. PubMed ID: 30451329
[TBL] [Abstract][Full Text] [Related]
7. Matrix remodelling and MMP expression/activation are associated with hidradenitis suppurativa skin inflammation.
Sanchez J; Le Jan S; Muller C; François C; Renard Y; Durlach A; Bernard P; Reguiai Z; Antonicelli F
Exp Dermatol; 2019 May; 28(5):593-600. PubMed ID: 30903721
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa.
Thomi R; Yerly D; Yawalkar N; Simon D; Schlapbach C; Hunger RE
Br J Dermatol; 2017 Nov; 177(5):1358-1366. PubMed ID: 28301691
[TBL] [Abstract][Full Text] [Related]
9. Chitinase-3-Like Protein 1 (YKL-40) Is a New Biomarker of Inflammation in Psoriasis.
Salomon J; Matusiak Ł; Nowicka-Suszko D; Szepietowski JC
Mediators Inflamm; 2017; 2017():9538451. PubMed ID: 28932021
[TBL] [Abstract][Full Text] [Related]
10. Reduced ten-eleven translocation and isocitrate dehydrogenase expression in inflammatory hidradenitis suppurativa lesions.
Hessam S; Gambichler T; Skrygan M; Sand M; Rüddel I; Scholl L; Bechara FG
Eur J Dermatol; 2018 Aug; 28(4):449-456. PubMed ID: 30325321
[TBL] [Abstract][Full Text] [Related]
11. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous PGP 9.5 distribution patterns in hidradenitis suppurativa.
Sartorius K; Emtestam L; Lapins J; Johansson O
Arch Dermatol Res; 2010 Aug; 302(6):461-8. PubMed ID: 20091410
[TBL] [Abstract][Full Text] [Related]
13. The microRNA effector RNA-induced silencing complex in hidradenitis suppurativa: a significant dysregulation within active inflammatory lesions.
Hessam S; Sand M; Skrygan M; Bechara FG
Arch Dermatol Res; 2017 Sep; 309(7):557-565. PubMed ID: 28634830
[TBL] [Abstract][Full Text] [Related]
14. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents.
Matusiak Ł; Szczęch J; Bieniek A; Nowicka-Suszko D; Szepietowski JC
J Am Acad Dermatol; 2017 Apr; 76(4):670-675. PubMed ID: 28041632
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
16. Integrating the skin and blood transcriptomes and serum proteome in hidradenitis suppurativa reveals complement dysregulation and a plasma cell signature.
Hoffman LK; Tomalin LE; Schultz G; Howell MD; Anandasabapathy N; Alavi A; Suárez-Fariñas M; Lowes MA
PLoS One; 2018; 13(9):e0203672. PubMed ID: 30265680
[TBL] [Abstract][Full Text] [Related]
17. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression.
Navrazhina K; Garcet S; Zheng X; Hur HB; Frew JW; Krueger JG
J Allergy Clin Immunol; 2022 Jan; 149(1):135-144.e12. PubMed ID: 34081946
[TBL] [Abstract][Full Text] [Related]
18. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS).
Hessam S; Sand M; Gambichler T; Bechara FG
J Am Acad Dermatol; 2015 Dec; 73(6):998-1005. PubMed ID: 26410359
[TBL] [Abstract][Full Text] [Related]
19. The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris.
Navrazhina K; Garcet S; Frew JW; Zheng X; Coats I; Guttman-Yassky E; Krueger JG
J Am Acad Dermatol; 2022 Feb; 86(2):322-330. PubMed ID: 34339761
[TBL] [Abstract][Full Text] [Related]
20. Chitinase-3-like Protein 1 (YKL-40) Expression in Squamous Cell Skin Cancer.
Salomon J; Piotrowska A; Matusiak Ł; Dzięgiel P; Szepietowski JC
Anticancer Res; 2018 Aug; 38(8):4753-4758. PubMed ID: 30061245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
